AKT1 and ovarian cancer: Network #3 represented reduced TGFBI abundance to derive the PI3 K/AKT pathway inhibition, a common manifestation in cancer [61], and the JAK/STAT signaling pathway, which is proposed as a new target for ovarian cancer anticancer drug resistance [62,63], is dysregulated in network #8 and other signaling pathways associated with ovarian are shown in Figure S1.